NASDAQ:GLMD Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis $1.41 -0.05 (-3.09%) Closing price 04:00 PM EasternExtended Trading$1.42 +0.02 (+1.06%) As of 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Galmed Pharmaceuticals Stock (NASDAQ:GLMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Galmed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.40▼$1.5050-Day Range$1.27▼$2.3352-Week Range$1.15▼$23.80Volume182,825 shsAverage Volume1.01 million shsMarket Capitalization$2.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials. In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders. The company leverages strategic partnerships for manufacturing and formulation development while pursuing regulatory approvals in key markets. Its clinical trial activities span North America and Europe, with trial sites designed to support potential future commercialization in regions where NASH represents a substantial unmet medical need. Founded in 2001 and headquartered in Tel Aviv, Israel, Galmed maintains corporate offices in the United States to facilitate interactions with regulatory agencies, clinical investigators and potential commercial partners. The company’s leadership team combines expertise in pharmaceutical development, hepatology and global commercialization strategy. Galmed Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol GLMD and remains committed to advancing therapies for patients suffering from progressive liver disease.AI Generated. May Contain Errors. Read More Galmed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreGLMD MarketRank™: Galmed Pharmaceuticals scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Galmed Pharmaceuticals.Read more about Galmed Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Galmed Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galmed Pharmaceuticals is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalmed Pharmaceuticals has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Galmed Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.18% of the float of Galmed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverGalmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galmed Pharmaceuticals has recently increased by 35.64%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalmed Pharmaceuticals does not currently pay a dividend.Dividend GrowthGalmed Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.18% of the float of Galmed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverGalmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galmed Pharmaceuticals has recently increased by 35.64%, indicating that investor sentiment is decreasing significantly. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Galmed Pharmaceuticals this week, compared to 0 articles on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Galmed Pharmaceuticals' insider trading history. Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLMD Stock News HeadlinesGalmed Pharmaceuticals (NASDAQ:GLMD) Downgraded to Sell Rating by Wall Street ZenAugust 31, 2025 | americanbankingnews.comGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 28, 2025 | finanznachrichten.deNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 trillion calculations per second. Elon Musk and Nvidia’s Jensen Huang are now teaming up to deploy one million of these chips inside what could become the most advanced AI machine on the planet. But according to James Altucher, the real opportunity isn’t in Tesla or Nvidia. He’s uncovered a little-known company that Musk, Nvidia, and even 98% of the Fortune 500 already rely on to make AI 2.0 possible. Nvidia’s CEO has even called this company “essential” to their expansion.September 10 at 2:00 AM | Paradigm Press (Ad)Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 28, 2025 | prnewswire.comGalmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder ValueAugust 25, 2025 | prnewswire.comGalmed Pharmaceuticals Amends Articles of Association Following Shareholder ApprovalAugust 15, 2025 | msn.comGalmed Pharmaceuticals Reschedules Shareholder Meeting Due to Lack of QuorumAugust 14, 2025 | tipranks.comGalmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASHMay 27, 2025 | prnewswire.comSee More Headlines GLMD Stock Analysis - Frequently Asked Questions How have GLMD shares performed this year? Galmed Pharmaceuticals' stock was trading at $3.19 at the beginning of 2025. Since then, GLMD stock has decreased by 55.8% and is now trading at $1.41. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) released its quarterly earnings data on Thursday, May, 22nd. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter. When did Galmed Pharmaceuticals' stock split? Galmed Pharmaceuticals shares reverse split on Monday, May 15th 2023.The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol Myers Squibb (BMY), Plug Power (PLUG), Applied Genetic Technologies (AGTC) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings5/22/2025Today9/10/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GLMD CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees20Year Founded2000Profitability EPS (Trailing Twelve Months)($16.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.52 million Net MarginsN/A Pretax MarginN/A Return on Equity-20.69% Return on Assets-18.41% Debt Debt-to-Equity RatioN/A Current Ratio8.71 Quick Ratio8.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.87 per share Price / Book0.15Miscellaneous Outstanding Shares1,650,000Free Float1,327,000Market Cap$2.40 million OptionableNot Optionable Beta0.56 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:GLMD) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s reported death a hoaxHow Trump’s latest policies could trigger a full-scale debt collapse… And the specific investments that cou...Porter & Company | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
